Sanofi-Aventis to double consumer health business in Canada with buy of Canderm; gets positive view on Multaq in France

16 June 2010

In a further move of its declared intention to expand its consumer health care business, French drug major Sanofi-Aventis has entered into a definitive agreement under which its Canadian affiliate will acquire the assets of Canderm Pharma, a privately-held leading Canadian skin care company. This deal follows on the heels of the group's $1.9 billion acquisition of the North American CHC company Chattem (The Pharma Letter December 22, 2009). Financial of the Canderm buy were not disclosed.

This transaction will allow Sanofi-Aventis to consolidate its dermatology portfolio under the Canderm umbrella to create a Canadian leader in medical dermatology, and to double its consumer health care sales in Canada. Canderm annual sales reached C$24 million ($23.2 million) in 2009, or approximately 10% of the non-prescription anti-ageing skin care market in Canada.

'The acquisition of the business of Canderm fits perfectly with our strategy of becoming a diversified health care company and is yet another important step in our strategy to build a sustainable long-term business model,' said Hugh O'Neill, president and chief of Sanofi-Aventis Canada, adding: 'It also offers new opportunities, as we plan to consolidate our dermatology portfolio under the Canderm umbrella to create a Canadian leader in medical dermatology.'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical